Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer molecular libraries

MedKoo product information:

Description of SR-31747:   SR-31747A is a synthetic peripheral sigma receptor ligand with immunomodulatory and potential antitumor activities. Although the exact mechanism by which SR31747A exerts its antitumor effects has not been fully established, SR31747A binds to and inhibits the sigma1 receptor (SR31747A-binding protein-1 or SR-BP1), human sterol isomerase (emopamil-binding protein) and the sigma2 receptor, which may result in a reduction in tumor cell proliferation and tumor cell apoptosis. In addition, this agent inhibits the production of pro-inflammatory cytokines while increasing anti-inflammatory cytokines. Upregulated in various cancers, the sigma1 and sigma2 receptors and human sterol isomerase are proteins that are involved in the regulation of cell proliferation and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Current developer:  Sanofi-Aventis Inc

SR 31747 is a novel immunosuppressant agent that arrests cell proliferation in the yeast Saccharomyces cerevisiae, SR 31747-treated cells accumulate the same aberrant sterols as those found in a mutant impaired in delta 8- delta 7-sterol isomerase. (from MCB).

SR31747 was shown to inhibit Δ8-Δ7 sterol isomerase in yeast. SR31747 is a high affinity ligand of recombinant mammalian sterol isomerase (Kd = 1 nM). For detail, please see: Pharmacology and Experimental Therapeutics

1: SR 31747. Peripheral sigma receptor antagonist. Drugs R D. 1999 Jan;1(1):108-9. PubMed PMID: 10566002.

2: Silve S, Leplatois P, Josse A, Dupuy PH, Lanau C, Kaghad M, Dhers C, Picard C, Rahier A, Taton M, Le Fur G, Caput D, Ferrara P, Loison G. The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol Cell Biol. 1996 Jun;16(6):2719-27. PubMed PMID: 8649379; PubMed Central PMCID: PMC231262.

3: Carayon P, Petitpretre G, Bourrie B, Le Fur G, Casellas P. In vivo effects of a new immunosuppressive sigma ligand, SR 31747, on mouse thymus. Immunopharmacol Immunotoxicol. 1996 May;18(2):179-91. PubMed PMID: 8771366.

4: Carayon P, Bouaboula M, Loubet JF, Bourrie B, Petitpretre G, Le Fur G, Casellas P. The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-gamma and GM-CSF mRNA expression. Int J Immunopharmacol. 1995 Sep;17(9):753-61. PubMed PMID: 8582787.

5: Derocq JM, Bourrié B, Ségui M, Le Fur G, Casellas P. In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747. J Pharmacol Exp Ther. 1995 Jan;272(1):224-30. PubMed PMID: 7815336.

6: Casellas P, Bourrié B, Canat X, Carayon P, Buisson I, Paul R, Brelière JC, Le Fur G. Immunopharmacological profile of SR 31747: in vitro and in vivo studies on humoral and cellular responses. J Neuroimmunol. 1994 Jul;52(2):193-203. PubMed PMID: 8034758.

7: Paul R, Lavastre S, Floutard D, Floutard R, Canat X, Casellas P, Le Fur G, Brelière JC. Allosteric modulation of peripheral sigma binding sites by a new selective ligand: SR 31747. J Neuroimmunol. 1994 Jul;52(2):183-92. PubMed PMID: 7794416.